Once-daily aminoglycoside therapy

Area of Science:

• Pharmacology and Infectious Diseases

Background:

• Once-daily administration of aminoglycosides presents an attractive therapeutic option.
• Existing animal and clinical data suggest reduced or unchanged toxicity risk with less frequent dosing.
• Reduced dosing frequency minimizes drug contact time with host tissues, potentially mitigating toxicity.

Purpose of the Study:

• To evaluate the efficacy and safety of once-daily aminoglycoside administration.
• To explore the role of the post-antibiotic effect (PAE) in maintaining antibacterial activity.
• To assess the implications of this dosing strategy in neutropenic patients.

Main Methods:

• Review of animal experiments and clinical trial data.
• Analysis of pharmacokinetic and pharmacodynamic principles, including PAE.
• Consideration of concurrent beta-lactam therapy in specific patient populations.

Main Results:

• Less frequent dosing does not appear to impair antibacterial efficacy, likely due to PAE.
• Higher peak serum concentrations may enhance early antibacterial activity within a dosage interval.
• In neutropenic patients, the in vivo PAE may be diminished or altered, potentially necessitating combined therapy.

Conclusions:

• International trial results are encouraging for once-daily aminoglycoside therapy.
• Despite pending US trial data, cautious implementation is warranted due to potential patient benefits.
• Infectious disease specialists should begin educating on the adoption of this dosing strategy.